Bristol Myers Squibb (CELG-RI) Total Debt (2009 - 2026)

Bristol Myers Squibb has disclosed Total Debt across 18 years of filings, most recently posting $44.5 billion for Q1 2026.

• In Q1 2026, Total Debt fell 10.56% year-over-year to $44.5 billion; the TTM figure through Mar 2026 stood at $44.5 billion (down 10.56% YoY), while the FY2025 annual figure was $45.1 billion, down 9.14% from the prior year.
• Total Debt fell to $44.5 billion in Q1 2026, from $45.1 billion in the prior quarter.
• Over the last five years, Total Debt for CELG-RI reached as high as $55.7 billion in Q1 2024 and fell as low as $37.6 billion in Q3 2023.
• The 5-year median for Total Debt is $45.0 billion (2022), against an average of $44.9 billion.
• Annual changes were most pronounced in 2023 — Total Debt retreated 15.88% — and 2024, when it surged 47.18%.
• A 5-year view of Total Debt shows it stood at $39.3 billion in 2022, then advanced by 1.15% to $39.8 billion in 2023, then advanced by 24.83% to $49.6 billion in 2024, then fell by 9.14% to $45.1 billion in 2025, then retreated by 1.44% to $44.5 billion in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $44.5 billion, $45.1 billion, and $49.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.